¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lipoprotein polymorphism"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polymorphism
    ´ÙÇüÅÂ, ¹µÇüÅÂ, ¿©·¯ÇüÅÂ
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇüÅÂ
  • single nucleotide polymorphism
    ´ÜÀÏ´ºÅ¬·¹¿ÀƼµå´ÙÇüÅÂ
  • high density lipoprotein
    °í¹ÐµµÁöÁú´Ü¹éÁú
  • intermediate density lipoprotein
    Á߹еµÁöÁú´Ü¹éÁú
  • lipoprotein
    ÁöÁú´Ü¹éÁú
  • lipoprotein lipase
    ÁöÁú´Ü¹éÁöÁúºÐÇØÈ¿¼Ò
  • low density lipoprotein
    Àú¹ÐµµÁöÁú´Ü¹éÁú
  • pre-beta-lipoprotein
    ÇÁ¸®º£Å¸ÁöÁú´Ü¹éÁú
  • very low density lipoprotein
    ÃÊÀú¹ÐµµÁöÁú´Ü¹éÁú
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polymorphism
    ´ÙÇüÅÂ, ¿©·¯ÇüÅÂÁõ
  • lipoprotein
    ÁöÁú´Ü¹é
  • high density lipoprotein
    °í¹ÐµµÁöÁú´Ü¹é
  • low density lipoprotein
    Àú¹ÐµµÁöÁú´Ü¹é
  • very low density lipoprotein
    ÃÊÀú¹ÐµµÁöÁú´Ü¹é
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polymorphism
    ´ÙÇüÅÂ, ¿©·¯ÇüÅÂÁõ
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇü¼º
  • high-density lipoprotein
    °í¹ÐµµÁöÁú´Ü¹é
  • intermediate density lipoprotein
    Á߹еµÁöÁú´Ü¹é
  • lipoprotein
    ÁöÁú´Ü¹é
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • DNA polymorphism
    DNA ´ÙÇü¼º
  • polymorphism
    ´ÙÇüÁõ
  • polymorphism
    ´ÙÇüÁõ(Òýû¡à÷ñø)
  • polymorphism
    ´ÙÇü¼ºÁõ
  • polymorphism
    ´ÙÇü, ´ÙÇüÅÂ
  • polymorphism
    ´ÙÇü¼º(Òýû¡à÷), ´ÙÇüÇö»ó(Òýû¡úÞßÚ)
  • polymorphism
    ´ÙÇü¼º(Òýúþàõ)
  • High-density lipoprotein = HDL
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • IDL = intermediate density lipoprotein
    Á߹еµÁö´Ü¹é(ñéÚËÓøò·Ó±ÛÜ)
  • Intermediate density lipoprotein =IDL
    Á߹еµÁö´Ü¹é(ñéÚËÓøò·Ó±ÛÜ)
  • LDL = low density lipoprotein
    Àú¹ÐµµÁö´Ü¹é(î¸ÚËÓøò·Ó±ÛÜ)
  • Lipoprotein
    Áö´Ü¹é(ò·Ó±ÛÜ)
  • Lipoprotein lipase
    Áö´Ü¹é(ò·Ó±ÛÜ) Áö¹æºÐÇØÈ¿¼Ò(ò·Û¸ÝÂú°ý£áÈ)
  • Lp(a) lipoprotein
    Lp(a) Áö´Ü¹é
  • LpX lipoprotein
    LpX Áö´Ü¹é
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • pharmacogenetic polymorphism
    ¾à¹°À¯ÀüÇÐÀû ´ÙÇü¼º.
  • polymorphism
    ´ÙÇü, ´ÙÇüÅÂ
  • polymorphism
    ´ÙÇü¼º(Òýû¡à÷), ´ÙÇüÇö»ó(Òýû¡úÞßÚ)
  • polymorphism
    ´ÙÇü¼º(Òýúþàõ)
  • polymorphism
    ´ÙÇüÁõ
  • polymorphism
    ´ÙÇüÁõ(Òýû¡à÷ñø)
  • polymorphism
    ´ÙÇü¼ºÁõ
  • restriction fragment length polymorphism
    Á¦ÇѼ¼Æí±æÀÌ´ÙÇü¼º(ð¤ùÚ¼¼Æí¡­Òýû¡à÷)
  • restriction fragment length polymorphism,in cystic fibrosis
    ³¶¼º¼¶À¯Áõ(ÀÇ)¡­(Ò¥àõàéë«ñø¡­)
  • restriction fragment length polymorphism analysis
    Á¦ÇÑÀý´Ü±æÀÌ´ÙÇüÁõºÐ¼®
  • restriction fragment length polymorphism=RFLP
    Á¦ÇÑÀýÆí±æÀ̴پ缺
  • beta-lipoprotein
    º£Å¸-Áö´Ü¹é<--ÁöÁú´Ü¹éÁú>
  • dyslipoproteinemia lipoprotein
    ÀÌ»óÁö¹æ´Ú¹éÇ÷Á¾ Áö¹æ´Ü¹é
  • familial high density lipoprotein def
    °¡Á·¼º °íºñÁ߸®Æ÷´Ü¹éÁú°áÇÌ Áõ.
  • high-density lipoprotein
    °í¹ÐµµÁö¹æ´Ü¹é
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • DNA polymorphism
    DNA ´ÙÇü¼º(Òýúþàõ) (ÔÒ) restriction fragment length polymorphism
  • polymorphism
    ´ÙÇü¼º(Òýúþàõ)
  • restriction fragment length polymorphism
    Á¦ÇÑ Á¶°¢±æÀÌ ´ÙÇü¼º(Òýúþàõ)
  • restriction polymorphism
    Á¦ÇÑ ´ÙÇü¼º(Òýúþàõ)
  • beta lipoprotein
    º£Å¸ ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • broad-beta lipoprotein
    ±¤´ë(ÎÆÓá) º£Å¸ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • familial high-density lipoprotein deficiency °¡Á·¼º °í¹Ðµµ ÁöÁú´Ü¹éÁú °áÇÌ (Ê«ðéàõÍÔÚËÓøò·òõ
    Ó±ÛÜòõÌÀù¹)
  • floating beta lipoprotein
    ºÎÀ¯(Ý©ë´) º£Å¸ ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • high-density lipoprotein
    °í¹Ðµµ ÁöÁú´Ü¹éÁú(ÍÔÚËÓøò·òõÓ±ÛÜòõ)
  • high-lipid lipoprotein
    °íÁöÁú ÁöÁú´Ü¹éÁú(ÍÔò·òõò¢òõÓ±ÛÜòõ)
  • lipoprotein
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • lipoprotein lipase
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ) ¶óÀÌÆäÀ̽º
  • lipoprotein tissue factor
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ) Á¶Á÷ÀÎÀÚ(ðÚòÄì×í­)
  • low-density lipoprotein
    Àú¹Ðµµ Áö´Ü¹éÁú(î¸ÚËÓøò·Ó±ÛÜòõ)
  • low-lipid lipoprotein
    ÀúÁöÁú Áö´Ü¹éÁú(î¸ò·òõò·Ó±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IRDP insulin-related DNA polymorphism
PIC Personality Inventory for Children; polymorphism information content
RELP restriction fragment length polymorphism
RFLP restriction fragment length polymorphism
SSCP single-stranded conformational polymorphism
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LDL-C lipoprotein cholesterol and low-density lipoprotein cholesterol
AFLP Amplified Fragment Length Polymorphism
FAFLP Fluorescent Amplified Fragment Length Polymorphism
PCR-SSCP PCR single-strand conformation polymorphism
RFLP PCR)-Restriction fragment length polymorphism
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • polymorphism
    ´ÙÇü, ´ÙÇüÁõ, ´ÙÇü¼º, ´ÙÇü Çö»ó
    °°Àº È­ÇÐ Á¶¼ºÀ» °®Áö¸¸, °áÁ¤ ±¸Á¶¸¦ ´Þ¸®ÇÏ´Â ¹°Áú. µ¿Áú ´ÙÇü ¶Ç´Â µ¿Áú ´Ù»óÀ̶ó°íµµ ÇÑ´Ù.
  • beta-lipoprotein
    º£Å¸ Áö¹æ ´Ü¹é
    Ç÷Áß ÁöÁú·Î Ư¼öÇÑ ¾ÆÆ÷ ´Ü¹éÀÌ °áÇÕµÈ °ÍÀ» ¸®Æ÷ ´Ü¹éÀ̶ó°í Çϴµ¥ ±× Áß¿¡¼­ Àü±â¿µµ¿¿¡ ÀÇÇØ¼­ º£Å¸ ±Û·ÎºÒ¸°ÀÇ ºÎÀ§¿¡ °ËÃâµÇ´Â °Í.
  • dyslipoproteinemia lipoprotein
    ÀÌ»ó Áö¹æ ´Ü¹éÇ÷Á¾ Áö¹æ ´Ü¹é
  • high-density lipoprotein
    °í¹Ðµµ Áö¹æ ´Ü¹é
  • lipoprotein metabolism disorer
    Áö´Ü¹é ´ë»ç Àå¾Ö
  • low-density lipoprotein
    Àú¹Ðµµ Áö¹æ ´Ü¹é
  • very low density lipoprotein
    ÃÊÀú ºñÁß Áö´Ü¹é, ÃÊÀú ºñÁß ÁöÁú ´Ü¹é, ÃÊÀú ºñÁß Áö´Ü¹éÁú, ÃÊÀú ºñÁß ÁöÁú ´Ü¹éÁú, ÃÊÀúºñÁß Áö¹æ ´Ü¹é
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
lipoprotein polymorphism Heritable variations in low density beta-lipoproteins; the variant lipoproteins exhibit different antigenic and chemical properties when compared with normal lipoproteins.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
amplified fragment length polymorphism <technique> Invented by KeyGene, a Dutch biotech company based in Wageningen, Holland. The technique is now merchandised under licence agreement by Perkin Elmer.
Selected markers are amplified in a PCR, which makes amplified fragment length polymorphism an easy and fast tool for strain identification in agriculture, botany, microbiology and animal breeding.
Acronym: AFLP
(05 Feb 1998)
balanced polymorphism <genetics> A type of polymorphism where the many morphs are alleles. The polymorphism is maintained in a population rather than the norm of one allele eventually becoming the only allele in the population, because individuals who are heterozygous, or have two different alleles, are more adaptive (more fit) than individuals who are homozygous, or have two copies of the same allele.
(09 Oct 1997)
genetic polymorphism The occurrence in the same population of multiple discrete alletic states of which at least two have high frequency (conventionally of 1% or more).
(05 Mar 2000)
restriction fragment length polymorphism <molecular biology, technique> A method that allows familial relationships to be established by comparing the characteristic polymorphic patterns that are obtained when certain regions of genomic DNA are amplified (typically by PCR) and cut with certain restriction enzymes.
The variation in the length of DNA fragments produced by a restriction endonuclease that cuts at a polymorphic locus. Such variations are generated by mutations that create or abolish recognition sites for these enzymes.
This is a key tool in DNA fingerprinting, reflecting the existence of different alleles in the individual. Restriction fragment length polymorphism mapping is also used in plant breeding to see if a key trait such as disease resistance is inherited.
In principle, an individual can be identified unambiquously by restriction fragment length polymorphism hence the use of restriction fragment length polymorphism in forensic analysis of blood, hair or semen).
Similarly, if a polymorphism can be identified close to the locus of a genetic defect, it provides a valuable marker for tracing the inheritance of the defect.
Synonym: DNA fingerprinting.
Acronym: RFLP
(12 Jan 1998)
restriction length polymorphism Fragment length polymorphism, the existence of allelic forms recognizable by the length of fragments that result when the nucleotide chain is treated by a specific restriction enzyme that cleaves wherever a particular sequence of nucleotides occurs. A mutation in this sequence changes cleaving and hence the number of fragments.
(05 Mar 2000)
restriction-site polymorphism DNA polymorphism in which the sequence of one form of the polymorphism contains a recognition site for a particular endonuclease, but the sequence of the other form lacks such a site.
(05 Mar 2000)
corneal endothelial polymorphism A greater than normal variation in the shape of the cells.
(05 Mar 2000)
polymorphism 1. <genetics> The regular and simultaneous occurrence in a single interbreeding population of two or more alleles of a gene, where the frequency of the rarer alleles is greater than can be explained by recurrent mutation alone (typically greater than 1%). The concept includes chromosome polymorphism.
HLA alleles of the major histocompatibility complex are very polymorphic.
2. <zoology> The differentiation of various parts of the units of colonial animals into different types of unit specialised for different purposes, for example as in the colonial hydroid Obelia.
(04 Jul 1999)
polymorphism, single-stranded conformational Variation occurring within a species in the conformation of denatured DNA fragments. These single-stranded DNA fragments are allowed to partially renature in a way that prevents the formation of double-stranded DNA. The fragments are run on polyacrylamide gels under various conditions to detect subtle changes in migration due to altered secondary structure. The resulting bands will align themselves if the fragments are the same, but will misalign if any point mutations are present. Sscps have been used in detecting mutations in various genes, such as oncogenes, tumour suppressor genes, and genes responsible for genetic diseases.
(12 Dec 1998)
single stranded conformational polymorphism Technique for detecting point mutations in genes by amplifying a region of genomic DNA (using asymmetric PCR) and running the resulting product on a high quality gel. Single base substitutions can alter the secondary structure of the fragment in the gel, producing a visible shift in its mobility.
(18 Nov 1997)
DNA polymorphism A condition in which one of two different but normal nucleotide sequences can exist at a particular site in DNA.
(05 Mar 2000)
a1-lipoprotein A lipoprotein fraction of relatively low molecular weight, high density, rich in phospholipids, and found in the a1-globulin fraction of human plasma.
(05 Mar 2000)
b1-lipoprotein A lipoprotein fraction of relatively high molecular weight, low density, rich in cholesterol, and found in the beta-globulin fraction of human plasma.
(05 Mar 2000)
receptors, lipoprotein Cell surface proteins that bind lipoproteins with high affinity. Lipoprotein receptors in the liver and peripheral tissues mediate the regulation of plasma and cellular cholesterol metabolism and concentration. The receptors generally recognise the apolipoproteins of the lipoprotein complex, and binding is often a trigger for endocytosis.
(12 Dec 1998)
very low density lipoprotein <biochemistry> A lipoprotein substances (combination of a fat and a protein) which acts as a carrier for cholesterol and fats (particularly triglycerides) in the bloodstream.
Elevations in very low density lipoprotein in the bloodstream are associated with an increased risk of atherosclerosis and coronary artery disease.
Acronym: VLDL
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipoprotein
    Áö´Ü¹éÁú;¸®Æ÷ ´Ü¹éÁú
  • polymorphism
    ´ÙÇü;µ¿Áú ÀÌ»ó;µ¿Áú ´Ù»ó
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á